Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MV-ZIKA dose finding in healthy volunteers
NCT02996890Phase 1Completed
- Sponsor
- Themis Bioscience
- Start
- May 2017
- Primary completion
- Jan 2018
- Modality
- Viral Vector Vaccines, Live Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MV-ZIKA-RSP in Zika virus infection (4 arms), sponsored by Themis Bioscience. Primary endpoint: Functional anti-Zika antibodies at 56 days. Started May 2017; status: completed.
02
Drugs
MV-ZIKA-RSP
03
Conditions
Zika virus infection
Beyond the preview
Go deeper on NCT02996890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02996890.